Showing results (241-250 of 301) with videos related to
Sort By:
Pageof 31
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.Respiratory Research|November 1, 2019
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)James F Donohue, Edward Kerwin, Sanjay Sethi, et al.International Journal of Chronic Obstructive Pulmonary Disease|August 31, 2016
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study designStephen I Rennard, Fernando J Martinez, Klaus F Rabe, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 28, 2010
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measureNancy Kline Leidy, Teresa K Wilcox, Paul W Jones, et al.Respiratory Research|October 8, 2014
Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trialsNancy K Leidy, Lindsey T Murray, Brigitta U Monz, et al.Respiratory Medicine|April 20, 2026
Outcomes of Patients with COPD Before and After Initiation of Treatment with Budesonide/Glycopyrrolate/Formoterol Fumarate: Results from the US ARCTOS StudySanjay Sethi, Laurence Gozalo, Donna McMorrow, et al.Journal of Managed Care & Specialty Pharmacy|May 3, 2023
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterolSanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, et al.Annals of the American Thoracic Society|January 16, 2014
Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary diseaseHimanshu Desai, Karen Eschberger, Catherine Wrona, et al.Vaccine|July 31, 2017
Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone childrenDabin Ren, Anthony L Almudevar, Timothy F Murphy, et al.Infection and Immunity|May 16, 2018
Changes in IgA Protease Expression Are Conferred by Changes in Genomes during Persistent Infection by Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary DiseaseMary C Gallo, Charmaine Kirkham, Samantha Eng, et al.Pageof 31